, Tracking Stock Market Picks
Enter Symbol:
Alnylam Pharmaceuticals, Inc. (ALNY) [hlAlert]

Above Average
up 218.45 %

Alnylam Pharmaceuticals, Inc. (ALNY) upgraded to Above Average with price target $33 by Caris & Company

Posted on: Friday,  Feb 8, 2008  8:25 AM ET by Caris & Company

Caris & Company rated Above Average Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) on 02/08/2008, when the stock price was $32.94.
Since then, Alnylam Pharmaceuticals, Inc. has gained 218.46% as of 01/22/2016's recent price of $104.90.
If you would have followed this Caris & Company's recommendation on ALNY, you would have gained 218.45% of your investment in 2905 days.

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is applying its therapeutic expertise in RNAi to address significant medical needs, many of which cannot effectively be addressed with small molecules or antibodies, the current major classes of drugs. Alnylam is building a pipeline of RNAi therapeutics; its lead program is in Phase I human clinical trials for the treatment of respiratory syncytial virus infection, which is the leading cause of hospitalization in infants in the U.S. The company's leadership position in fundamental patents, technology, and know-how relating to RNAi has enabled it to form major alliances with leading companies including Merck, Medtronic, Novartis, and Biogen Idec.

Caris & Company, an investment bank created by a diverse group of leading Wall Street professionals. We are founded on the basic principle that Wall Street requires a different type of organization: One that offers objective, conflict-free research, acute focus on customer service, broad institutional coverage, and an unwavering commitment to increasing the value of our clients' portfolios. Quite simply, our goal is to generate solid investment ideas for our clients. We offer a unique, differentiated, conflict-free research perspective on large, mid, and small capitalization companies in four growth oriented verticals: Health Care, Technology, Energy, and Consumer.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
2/8/2008 8:25 AM Buy
32.94 33.00
as of 12/24/2008
1 Week down  -9.29 %
1 Month down  -7.66 %
3 Months down  -21.05 %
1 YTD down  -31.33 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
9/19/2007 9:25 AM Hold
31.65 30.00
7/10/2007 9:25 AM Buy
22.95 30.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy